JMIR Publications

ABSTRACT

Dengue fever can progress to dengue hemorrhagic fever (DHF), which is a more serious and occasionally fatal form of the disease. The patient may acquire warning indications of serious disease about the time the fever begins to reduce (typically 3–7 days following symptom onset), and there are currently no effective antivirals available. Drug repurposing is emerging as a novel drug discovery process for rapidly developing effective DHF therapies. Through network pharmacology modelling, several FDA-approved medications have already been researched for various viral outbreaks. By analysing the interactions between virus-host gene interactions and therapeutic targets in the human genome network, a total of 45 repurposable medicines were discovered. Hub network analysis of host-virus-drugs association hypothesised that aspirin, captopril, and rilonacept are efficient in the treatment of DHF, and gene enrichment analysis supports the findings. According to a Mayo Clinic report, using aspirin in the treatment of dengue fever may increase the risk of dengue fever bleeding complications, but several studies from around the world suggest the thrombosis associated with DHF. The human interactome contains the genes PTGS2, ACE, and F2, documented to have a role in the pathogenesis of disease progression in DHF, and our analysis of most of the drugs targeting these genes. As a result, genes targeting medications play a significant part in limiting the condition's advancement.